JP2015520758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520758A5 JP2015520758A5 JP2015512801A JP2015512801A JP2015520758A5 JP 2015520758 A5 JP2015520758 A5 JP 2015520758A5 JP 2015512801 A JP2015512801 A JP 2015512801A JP 2015512801 A JP2015512801 A JP 2015512801A JP 2015520758 A5 JP2015520758 A5 JP 2015520758A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- heavy chain
- antibody
- variable region
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261649110P | 2012-05-18 | 2012-05-18 | |
| US61/649,110 | 2012-05-18 | ||
| US13/804,227 | 2013-03-14 | ||
| US13/804,227 US20130309223A1 (en) | 2012-05-18 | 2013-03-14 | CD33 Antibodies And Use Of Same To Treat Cancer |
| PCT/US2013/041209 WO2013173496A2 (en) | 2012-05-18 | 2013-05-15 | Cd33 antibodies and use of same to treat cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520758A JP2015520758A (ja) | 2015-07-23 |
| JP2015520758A5 true JP2015520758A5 (cg-RX-API-DMAC7.html) | 2016-05-19 |
| JP6454269B2 JP6454269B2 (ja) | 2019-01-16 |
Family
ID=49581477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512801A Expired - Fee Related JP6454269B2 (ja) | 2012-05-18 | 2013-05-15 | Ｃｄ３３抗体及び癌を処置するためのその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20130309223A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3421048A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6454269B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102100467B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104936617B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013262788B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2873286C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2850104T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA029987B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2686618T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL235733B (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN10653A (cg-RX-API-DMAC7.html) |
| MX (1) | MX350808B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ702748A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201407610WA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI593707B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013173496A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201409224B (cg-RX-API-DMAC7.html) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2609932B1 (en) | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| KR102356814B1 (ko) | 2013-10-15 | 2022-01-28 | 씨젠 인크. | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 |
| SG10201710475WA (en) * | 2013-11-25 | 2018-01-30 | Seattle Genetics Inc | Preparing antibodies from cho cell cultures for conjugation |
| MA39095A1 (fr) * | 2013-12-13 | 2018-08-31 | Genentech Inc | Anticorps et immunoconjugués anti-cd33 |
| WO2015123265A1 (en) | 2014-02-11 | 2015-08-20 | Seattle Genetics, Inc. | Selective reduction of proteins |
| IL309933A (en) | 2014-02-17 | 2024-03-01 | Seagen Inc | Hydrophilic antibody-drug conjugates |
| CA2944528C (en) | 2014-04-03 | 2021-08-10 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| SG11201700416TA (en) * | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| CA2973529A1 (en) | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| SG10201912085WA (en) | 2015-06-12 | 2020-02-27 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| EA201890158A1 (ru) * | 2015-06-30 | 2018-06-29 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные композиции и способы |
| AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
| US20190117787A1 (en) * | 2016-04-15 | 2019-04-25 | Seattle Genetics, Inc. | Combinations of cd33 antibody drug conjugates with hypomethylating agents |
| WO2017210621A1 (en) * | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| EP3469001A4 (en) | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS |
| KR20190038579A (ko) | 2016-08-09 | 2019-04-08 | 시애틀 지네틱스, 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
| BR112019006778A2 (pt) | 2016-10-18 | 2019-10-15 | Seattle Genetics Inc | Composição de conjugado de aglutinante-fármaco, formulação, uso da mesma, método para preparar uma composição ou composto de conjugado de aglutinantefármaco,e, composto de ligante de fármaco |
| US10736976B2 (en) | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| IL266892B2 (en) | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| US11975029B2 (en) | 2017-02-28 | 2024-05-07 | Vor Biopharma Inc. | Compositions and methods for inhibition of lineage specific proteins |
| MX2019010028A (es) | 2017-02-28 | 2019-10-14 | Seattle Genetics Inc | Anticuerpos con cisteina mutada por conjugacion. |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| MA51189A (fr) | 2017-04-27 | 2020-03-04 | Seattle Genetics Inc | Conjugués d'inhibiteur de la voie de récupération du nicotinamide adénine dinucléotide quaternarisé |
| MA49152A (fr) * | 2017-05-17 | 2020-03-25 | Immunogen Inc | Schémas posologiques d'immunoconjugués anti-cd33 |
| US12116406B2 (en) * | 2017-05-26 | 2024-10-15 | Fred Hutchinson Cancer Center | Anti-CD33 antibodies and uses thereof |
| KR102733407B1 (ko) | 2017-08-03 | 2024-11-21 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
| TW202511296A (zh) | 2017-08-03 | 2025-03-16 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
| CA3126646A1 (en) | 2017-09-29 | 2019-04-04 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| MX2020008683A (es) * | 2018-02-20 | 2020-12-07 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpo que se dirigen a cd33 y sus usos. |
| IL276546B2 (en) | 2018-02-20 | 2024-08-01 | Seagen Inc | Hydrophobic auristatin F compounds and their conjugates |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CN113423725A (zh) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | 遗传工程化造血干细胞及其用途 |
| SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP4268831A3 (en) | 2018-09-12 | 2024-05-22 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
| JP2022501319A (ja) * | 2018-09-25 | 2022-01-06 | アカデミア シニカAcademia Sinica | 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用 |
| JP7553440B2 (ja) | 2018-11-07 | 2024-09-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 抗ｃｄ３３免疫細胞癌療法 |
| SG11202104993SA (en) | 2018-11-14 | 2021-06-29 | Daiichi Sankyo Co Ltd | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate |
| US12441793B2 (en) | 2019-02-22 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | CD33 antibodies and methods of using the same to treat cancer |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| BR112021017616A2 (pt) | 2019-03-25 | 2021-11-09 | Daiichi Sankyo Co Ltd | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
| CN113631191B (zh) | 2019-03-27 | 2024-09-27 | 第一三共株式会社 | 抗体－吡咯并苯并二氮杂卓衍生物偶联物与parp抑制剂的组合 |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| CA3142886A1 (en) * | 2019-06-06 | 2020-12-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| EP4126248A4 (en) * | 2020-03-31 | 2024-07-10 | Fred Hutchinson Cancer Center | HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES |
| WO2021202726A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| US20230173093A1 (en) | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| US20210402001A1 (en) * | 2020-06-30 | 2021-12-30 | David I. Cohen | Zinc Porters, and their Monoclonal Antibody Conjugates, for the Prevention and Treatment of COVID-19 (SARS-CoV-2), Other Infections, and Cancers |
| CN116113641A (zh) | 2020-09-02 | 2023-05-12 | 第一三共株式会社 | 新型内－β－N－乙酰氨基葡萄糖苷酶 |
| CN117295767A (zh) * | 2020-11-11 | 2023-12-26 | Versapeutics公司 | 针对wnt受体ryk的抗体变体 |
| MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
| CN117062611A (zh) | 2021-01-26 | 2023-11-14 | 惠和生物技术(上海)有限公司 | 嵌合抗原受体（car）构建体和表达car构建体的nk细胞 |
| WO2022198231A1 (en) | 2021-03-18 | 2022-09-22 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN117597150A (zh) | 2021-04-20 | 2024-02-23 | 思进公司 | 抗体依赖性细胞毒性的调节 |
| CN117580593A (zh) | 2021-05-28 | 2024-02-20 | 思进公司 | 蒽环霉素抗体结合物 |
| AU2022401024A1 (en) | 2021-11-30 | 2024-05-16 | Daiichi Sankyo Company, Limited | Protease-cleavable masked antibodies |
| EP4477674A1 (en) | 2022-02-09 | 2024-12-18 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| CN118804983A (zh) | 2022-03-02 | 2024-10-18 | 第一三共株式会社 | 含Fc分子的制造方法 |
| CA3254933A1 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| CN116375874B (zh) * | 2023-04-14 | 2023-12-26 | 上海精翰生物科技有限公司 | 一种cd33抗体及其应用 |
| WO2025090774A1 (en) | 2023-10-24 | 2025-05-01 | Seagen Inc. | Chemotherapeutic compounds and methods of use |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
| WO2025174974A1 (en) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anti-cd33 antibodies and uses thereof |
| CN119080935A (zh) * | 2024-10-11 | 2024-12-06 | 上海市同仁医院 | 一种抗人SMIM45-107aa单克隆抗体及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CA2625839A1 (en) | 1999-02-05 | 2000-08-10 | Samsung Electronics Co., Ltd. | Image texture retrieving method and apparatus thereof |
| JP3888971B2 (ja) * | 2000-08-08 | 2007-03-07 | イムノメディクス， インコーポレイテッド | 慢性骨髄性白血病の免疫療法 |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| SI1578446T1 (sl) * | 2002-11-07 | 2015-07-31 | Immunogen, Inc. | Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega |
| US7419811B2 (en) | 2003-02-28 | 2008-09-02 | The Board Of Trustees Of The University Of Illinois | Use of specifically engineered enzymes to enhance the efficacy of prodrugs |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US8343928B2 (en) | 2005-07-07 | 2013-01-01 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus |
| US7910702B2 (en) | 2006-07-28 | 2011-03-22 | The Governors Of The University Of Alberta | Recombinant antibodies to sclerotinia antigens |
| EP2609932B1 (en) * | 2006-12-01 | 2022-02-02 | Seagen Inc. | Variant target binding agents and uses thereof |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102170907A (zh) * | 2008-08-05 | 2011-08-31 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| AU2010221993C1 (en) * | 2009-03-10 | 2015-07-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized K33N monoclonal antibody |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| CN103068405A (zh) * | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN104837508A (zh) * | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
| KR102274714B1 (ko) * | 2013-03-13 | 2021-07-09 | 씨젠 인크. | 사이클로덱스트린 및 항체-약물 포합체 제형 |
-
2013
- 2013-03-14 US US13/804,227 patent/US20130309223A1/en not_active Abandoned
- 2013-05-15 NZ NZ702748A patent/NZ702748A/en not_active IP Right Cessation
- 2013-05-15 SG SG11201407610WA patent/SG11201407610WA/en unknown
- 2013-05-15 EP EP18171884.2A patent/EP3421048A1/en not_active Withdrawn
- 2013-05-15 ES ES13790467.8T patent/ES2686618T3/es active Active
- 2013-05-15 JP JP2015512801A patent/JP6454269B2/ja not_active Expired - Fee Related
- 2013-05-15 DK DK13790467.8T patent/DK2850104T3/en active
- 2013-05-15 IN IN10653DEN2014 patent/IN2014DN10653A/en unknown
- 2013-05-15 AU AU2013262788A patent/AU2013262788B2/en not_active Ceased
- 2013-05-15 EP EP13790467.8A patent/EP2850104B1/en active Active
- 2013-05-15 US US14/401,837 patent/US9587019B2/en active Active
- 2013-05-15 CN CN201380026079.9A patent/CN104936617B/zh active Active
- 2013-05-15 MX MX2014013866A patent/MX350808B/es active IP Right Grant
- 2013-05-15 KR KR1020147035516A patent/KR102100467B1/ko active Active
- 2013-05-15 EA EA201492137A patent/EA029987B1/ru unknown
- 2013-05-15 KR KR1020207010113A patent/KR102241478B1/ko active Active
- 2013-05-15 CA CA2873286A patent/CA2873286C/en active Active
- 2013-05-15 WO PCT/US2013/041209 patent/WO2013173496A2/en not_active Ceased
- 2013-05-17 TW TW102117539A patent/TWI593707B/zh active
-
2014
- 2014-11-17 IL IL235733A patent/IL235733B/en unknown
- 2014-12-15 ZA ZA2014/09224A patent/ZA201409224B/en unknown
-
2017
- 2017-01-20 US US15/411,947 patent/US10787514B2/en active Active
-
2018
- 2018-05-17 AU AU2018203508A patent/AU2018203508C1/en not_active Ceased
-
2020
- 2020-05-22 AU AU2020203365A patent/AU2020203365B2/en not_active Ceased
- 2020-07-29 US US16/942,647 patent/US20210047404A1/en not_active Abandoned